When was Singular Bio founded?

Singular Bio was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Singular Bio located?

Singular Bio is headquartered in San Francisco, United States.

How many employees does Singular Bio have?

As of Jul 01, 2024, the latest employee count at Singular Bio is 11 - 50.

Is Singular Bio a funded company?

Singular Bio is a funded company, having raised a total of $6.58M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2013.

When was the latest funding round of Singular Bio?

Singular Bio's latest funding was a $***** Series A round on Feb 12, 2019, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $182M in funding in 2026 to date.

Where does Singular Bio rank among its competitors?

Singular Bio ranks 28th amongst 614 active competitors, of which 65 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was ONCOHOST, which secured $2.8M in May, 2025.

Who are the top competitors of Singular Bio?

Singular Bio's top competitors include Strand Life Sciences, Novogene Corporation and ONCOHOST. Among them, ONCOHOST secured the most recent funding round in May, 2025.

Singular Bio - 2026 Company Profile, Funding & Competitors

Q: Is Singular Bio an acquired company?

Singular Bio got acquired by Invitae on Jun 17, 2019.

Singular Bio is an acquired company based in San Francisco (United States), founded in 2012. It operates as a Tools for single molecule detection. Singular Bio has raised $6.58M in funding. The company has 614 active competitors, including 65 funded and 71 that have exited. Its top competitors include companies like Strand Life Sciences, Novogene Corporation and ONCOHOST.

Company Details

Singular Bio’s proprietary single molecule detection system takes a unique measurement for every molecule. The system achieves exceptional sensitivity by combining advanced optics with custom molecular biology and chemistry. Their screening platform is easy to use, flexible and offers scalable throughput, allowing it to be deployed in testing labs of any size, in any location.

Website: www.singularbio.com
Email ID: *****@singularbio.com

Key Metrics

Founded Year

2012

Location

San Francisco, United States

Stage

Acquired

Total Funding

$6.58M in 2 rounds

Latest Funding Round

Series A, Feb 12, 2019, $*****

Investors

The Vertical Group & 2 more

Ranked

28^th among 614 active competitors

Employee Count

11 - 50 as on Jul 01, 2024

Similar Companies

Strand Life Sciences & 765 more

Exit Details

Acquired by Invitae (Jun 17, 2019)

View Singular Bio's full profile

Singular Bio got acquired by Invitae on Jun 17, 2019 at an acquisition amount of $55M.

Click here to take a look at Singular Bio's acquisition in detail

Singular Bio has raised a total funding of $6.58M over 2 rounds. Its first funding round was on 2013. Singular Bio has 3 institutional investors.

Here is the list of recent funding rounds of Singular Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 12, 2019	6839481	Series A	6361150	8960984	1618729	8005810
2013	5199	Seed	6844	6739	6648	The Vertical Group

Access funding benchmarks and valuations. Sign up today!

View details of Singular Bio's funding rounds and investors

Singular Bio's employee count trend

Singular Bio has 11 - 50 employees as of Jul 24. Here is Singular Bio's employee count trend over the years:

Uncover Singular Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Singular Bio include Strand Life Sciences, Novogene Corporation and ONCOHOST. Here is the list of Top 10 competitors of Singular Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, Quadria Capital & 91 others	64/100
2nd	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	61/100
3rd	ONCOHOST 2017, Binyamina Giv at Ada (Israel), Series C	AI-based oncology therapy plan solution for professionals	$43M	OurCrowd, ALIVE & 5 others	61/100
4th	Genewiz 1999, South Plainfield (United States), Acquired	Provider of a wide range of genomic services for the life sciences industry	-	Kenson Ventures, Orbimed & 5 others	59/100
5th	deCODE Genetics 1996, Reykjavik (Iceland), Acquired	Provider of a bioinformatics platform for genetic analysis	-	Tekla Capital Management, Illumina Ventures ... & 10 others	58/100
6th	Biomodal 2012, Cambridge (United Kingdom), Series D	Developer of DNA sequencing tools and technology for research and diagnostics	$164M	New Science Ventures, Ahren & 23 others	58/100
7th	BGI 1999, Shenzhen (China), Public	Provider of services in genome sequencing	-	Fusion Capital, Sequoia Capital China & 15 others	54/100
8th	Source BioScience 1903, Nottingham (United Kingdom), Acquired	Provider of multiple genomic services	-	HPE	54/100
9th	Tavotek 2018, King Of Prussia (United States), Series B	Provider of drug discovery platform for different diseases	$35M	GF Xinde Investment Management, Yuanbio Venture Capital ... & 6 others	54/100
10th	Enara Bio 2016, Oxford (United Kingdom), Series B	Developer of T-cell based cancer-cell interface for therapeutics	$84.1M	SV Health Investors, M Ventures & 36 others	53/100
28th	Singular Bio 2012, San Francisco (United States), Acquired	Tools for single molecule detection	$6.58M	The Vertical Group, Prefix Capital & 1 others	44/100